extrahepatic cholangiocarcinoma

Proteogenomic Insights into Personalized Adjuvant Chemotherapy for Extrahepatic Cholangiocarcinoma

By MedXY 10/28/2025

Comprehensive proteogenomic profiling in resected extrahepatic cholangiocarcinoma reveals predictive biomarkers for tailoring adjuvant chemotherapy, offering a precision medicine approach to improve patient outcomes.

Clinical Updates news Oncology Pathology & Lab Medicine Specialties

Predictive Power of Circulating Tumor DNA in Managing Resected Extrahepatic Cholangiocarcinoma

By MedXY 09/20/2025

Monitoring circulating tumor DNA (ctDNA) post-surgery accurately predicts recurrence risk in extrahepatic cholangiocarcinoma, guiding personalized adjuvant chemotherapy decisions and improving patient outcomes.

Oncology Specialties

Advancing Adjuvant Therapy in Extrahepatic Cholangiocarcinoma and Gallbladder Cancer: Promising Results from Immunochemoradiation Trial

By MedXY 08/23/2025

The ACCORD trial demonstrates that combining camrelizumab with chemoradiotherapy significantly improves survival outcomes in resectable extrahepatic cholangiocarcinoma and gallbladder cancer, with an acceptable safety profile.